INJURY
HEMODYNAMIC AND METABOLIC DISTURBANCES
Objective: to study the conditions and mechanism of postischemic no-reflow and delayed hypoperfusion and to correct them with perfluorane.
Materials and methods: Both phenomena were reproduced by using a rat model of global cerebral ischemia.
Results: no-reflow was shown to be caused by pial arteriolar collapse that occurred in ischemia and lasted during reperfusion. Delayed postischemic hypoperfusion was induced by increased pial arteriolar tone.
Conclusion: Intraarterial injection of perfluorane alleviates the manifestation of both phenomena due to better oxygen supply to ischemic brain tissue and, probably, to calcium channel blockage.
ACUTE PANCREATITIS
Objective: to study the risk factors, clinical, laboratory, and functional manifestations, course, prevention, treatment, and outcome of reactive pancreatitis (RP) following endoscopic retrograde cholangiopancreatography (ERCP).
Subjects and methods: A study group comprised 207 patients (156 males and 51 females; mean age, 54.5±12.7 years) treated at the N. N. Burdenko Main Military Hospital and undergone ERCP with and without papillosphincterotomy (PST). The patients’ status, the presence and pattern of subjective and objective symptoms and laboratory parameters (blood amylase, urinary diastase, leukocytosis) were dynamically estimated after ERCP.
Results: 58 (28.0%) patients developed post-ERCP RP, the severe course of pancreatitis being observed in 4.3%. There were no cases of pancreatic necrosis or fatal outcomes. RP was significantly more common in females, persons under 50 years of age, patients with chronic pancreatitis, cholelithiasis, or major duodenal papillary abnormalities (duodenal papillitis, choledochal stricture), choledocholithiasis, in the absence of the dilated common bile duct. RP less frequently occurred in patients only when adequate or combined PST had been performed. RP was characterized by an acute course, with a significant pain syndrome occurring, by altered health status, fever, hyperamylasemia, and leukocytosis within the first-second days following ERCP, and delayed urinary diastase elevation. Just after ERCP, all the patients were given a combination of octreotide and a protease inhibitor to prevent RP. The efficiency of prevention was directly confirmed by the fact that there were no cases of pancreatic necrosis and fatal outcomes. To treat RP, the authors gave a combination of antisecretory agents, protease inhibitors (contrycal, ingitril), antibacterial drugs (cephalosporins, fluoroquinolones), and proton pump inhibitors during starvation, in the use of analgesics and spasmolytics, and during active infusion therapy. In all cases RP was benign and ended with the patients recovery 5—14 days after initiation of the therapy.
Conclusion: ERCP is a serious endoscopic operation characterized by a high risk of life-threatening complications (first of all RP). Before ERCP, the risk factors of RP should be assessed. All patients to undergo ERCP need a complex RP prevention including endoscopy, drugs, and intensive monitoring. In evolving RP, early multimodality therapy comprising antisecretory drugs, protease inhibitors, antibiotic therapy, analgesia, infusion therapy, and starvation.
PREGNANCY COMPLICATIONS
PREHOSPITAL RESUSCITATION
DIETOTHERAPY IN CRITICAL CONDITIONS
ACUTE RESPIRATORY FAILURE
FOR PRACTIONER
PROFESSIONAL EDUCATION
Chronicle
ISSN 2411-7110 (Online)